Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells.
NOTCH1
apoptosis
cell proliferation
malignant pleural mesothelioma
metformin
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
02
2020
accepted:
15
12
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer arising from the mesothelial cells lining the pleural cavity. MPM is characterized by a silent clinical progression and a highly resistance to conventional chemo/radio-therapies. MPM patients die in a few months/years from diagnosis. Notch signaling is a well-conserved cell communication system, which regulates many biological processes. In humans, the dysregulation of Notch pathway potentially contributes to cancer onset/progression, including MPM. Metformin is the first-line drug used to treat type 2 diabetes mellitus. Metformin is proven to be an effective antitumor drug in preclinical models of different types of cancer. To date, clinical efficacy is being studied in many clinical trials. In this study, the anti-proliferative effect of metformin on MPM cells and the putative involvement of Notch1 as a mediator of metformin activities, were investigated. MPM cells showed high levels of Notch1 activation compared to normal pleural mesothelial cells. Furthermore, metformin treatment hampered MPM cell proliferation and enhanced the apoptotic process, accompanied by decreased Notch1 activation.
Identifiants
pubmed: 33537296
doi: 10.3389/fcell.2020.534499
pmc: PMC7849608
doi:
Types de publication
Journal Article
Langues
eng
Pagination
534499Informations de copyright
Copyright © 2021 Rossini, Martini, Torreggiani, Fortini, Aquila, Vieceli Dalla Sega, Patergnani, Pinton, Maniscalco, Cavallesco, Rizzo and Tognon.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2018 Apr 03;8:91
pubmed: 29666782
Mol Cancer Res. 2011 May;9(5):603-15
pubmed: 21422199
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9
pubmed: 10954737
Cancer Res. 2008 Jul 1;68(13):5226-35
pubmed: 18593923
Eur Surg. 2017;49(5):199-209
pubmed: 29104587
Diabetes Care. 2010 Jul;33(7):1674-85
pubmed: 20587728
Oncotarget. 2016 Dec 13;7(50):82700-82711
pubmed: 27716620
Cell Physiol Biochem. 2015;36(5):1991-2002
pubmed: 26202359
EMBO Rep. 2014 Nov;15(11):1128-38
pubmed: 25252682
Curr Top Microbiol Immunol. 2012;360:99-114
pubmed: 22695917
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18066-71
pubmed: 23071320
Oncol Lett. 2018 Jan;15(1):683-690
pubmed: 29422962
PLoS One. 2012;7(3):e33411
pubmed: 22448244
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
Oncotarget. 2017 Mar 28;8(13):20706-20718
pubmed: 28157701
Int J Environ Res Public Health. 2018 May 16;15(5):
pubmed: 29772681
Pharmacol Ther. 2013 Aug;139(2):95-110
pubmed: 23458608
Sci Rep. 2019 May 29;9(1):7999
pubmed: 31142802
Expert Opin Drug Deliv. 2019 Apr;16(4):441-451
pubmed: 30916586
J Thorac Oncol. 2011 May;6(5):844-51
pubmed: 21358347
Cancer. 2011 Nov 15;117(22):5234-44
pubmed: 21523763
Oncogene. 2003 Jan 9;22(1):81-9
pubmed: 12527910
Oncotarget. 2015 Sep 15;6(27):23427-44
pubmed: 26156019
Oncogene. 2016 Apr 14;35(15):1996-2002
pubmed: 26119930
J Exp Clin Cancer Res. 2019 Feb 13;38(1):77
pubmed: 30760281
Front Immunol. 2018 Jun 04;9:1288
pubmed: 29915603
Science. 2000 May 12;288(5468):1053-8
pubmed: 10807576
Cancer Res. 2008 Nov 15;68(22):9488-96
pubmed: 19010924
Nat Genet. 2011 Aug 28;43(10):1022-5
pubmed: 21874000
Lung Cancer. 2016 Sep;99:194-9
pubmed: 27565939
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64
pubmed: 25850553
J Thorac Oncol. 2015 May;10(5):731-737
pubmed: 25668121
Oncol Lett. 2018 Aug;16(2):2030-2038
pubmed: 30008897
Cancer Res. 2008 Dec 1;68(23):9678-85
pubmed: 19047145
Development. 2013 Feb;140(4):689-704
pubmed: 23362343
Ann Cardiothorac Surg. 2012 Nov;1(4):491-6
pubmed: 23977542
Ann Transl Med. 2017 Jun;5(11):234
pubmed: 28706902
Curr Opin Cell Biol. 2018 Dec;55:1-7
pubmed: 30006050
Adv Exp Med Biol. 2018;1066:339-354
pubmed: 30030835
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
J Cell Physiol. 2012 Jan;227(1):44-58
pubmed: 21412769
Front Oncol. 2019 Jul 25;9:670
pubmed: 31403031
Oncogene. 2008 Dec;27 Suppl 1:S84-92
pubmed: 19641509
Oncotarget. 2016 Jun 28;7(26):40767-40780
pubmed: 27004404
Cell Metab. 2014 Dec 2;20(6):953-66
pubmed: 25456737
Zhonghua Yi Xue Za Zhi. 2015 Apr 28;95(16):1258-61
pubmed: 26081514
Molecules. 2018 Feb 15;23(2):
pubmed: 29462871
Oncotarget. 2016 Aug 2;7(31):49664-49676
pubmed: 27391069
Physiol Rev. 2017 Oct 1;97(4):1235-1294
pubmed: 28794168
EMBO Mol Med. 2017 Jul;9(7):950-966
pubmed: 28539479
Neoplasia. 2019 Jul;21(7):702-712
pubmed: 31129492
Curr Opin Cell Biol. 2018 Apr;51:103-109
pubmed: 29289895
Leukemia. 2012 Jun;26(6):1402-5
pubmed: 22094583
Oncogene. 2008 Sep 1;27(38):5124-31
pubmed: 18758481
J Cell Mol Med. 2011 Jan;15(1):166-78
pubmed: 19874425